• Sulbactam ([CP45,899] penicillanic acid sulfone) inhibits many of the β-lactamases commonly found to be the cause of penicillin resistance. This agent was combined with either penicillin G potassium or ampicillin sodium in the treatment of 97 patients admitted with serious soft-tissue infections. Fifty-one of the infections were caused by at least one bacteria resistant to the antibiotic alone. Staphylococcus aureus was the most common pathogen (48 isolations) followed by the coliforms (30 isolations). Ninety percent of the isolates that were tested produced β-lactamase. Susceptibility studies showed a high degree of resistance to the penicillin alone that was significantly lowered by the addition of sulbactam. The overall clinical results showed 81% of the infections to be either well controlled or cured. Three patients failed to show improvement. Thirteen patients showed transitory increases in liver function tests. This therapeutic regimen appears to be relatively safe and efficacious in the treatment of soft-tissue infection caused by penicillin-resistant and penicillin-susceptible organisms.
(Arch Surg 1985;120:36-42)
Lee Nichols R, Smith JW, Adinolfi MF, Galli R, Vivoda LM. Inhibition of β-Lactamase—Induced Resistance in Soft-Tissue Infections. Arch Surg. 1985;120(1):36–42. doi:10.1001/archsurg.1985.01390250030005
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.